264 related articles for article (PubMed ID: 29549837)
1. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
Eur J Med Chem; 2018 Apr; 150():506-524. PubMed ID: 29549837
[TBL] [Abstract][Full Text] [Related]
2. Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
ACS Chem Neurosci; 2019 Mar; 10(3):1765-1782. PubMed ID: 30525452
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
J Med Chem; 2016 Oct; 59(19):8967-9004. PubMed ID: 27606546
[TBL] [Abstract][Full Text] [Related]
4. Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease.
Sánchez-Arias JA; Rabal O; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; Ugarte A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
ACS Chem Neurosci; 2017 Mar; 8(3):638-661. PubMed ID: 27936591
[TBL] [Abstract][Full Text] [Related]
5. Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors.
ElHady AK; Shih SP; Chen YC; Liu YC; Ahmed NS; Keeton AB; Piazza GA; Engel M; Abadi AH; Abdel-Halim M
Bioorg Chem; 2020 May; 98():103742. PubMed ID: 32199305
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J
ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218
[TBL] [Abstract][Full Text] [Related]
7. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
8. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
9. A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.
Cuadrado-Tejedor M; Garcia-Barroso C; Sánchez-Arias JA; Rabal O; Pérez-González M; Mederos S; Ugarte A; Franco R; Segura V; Perea G; Oyarzabal J; Garcia-Osta A
Neuropsychopharmacology; 2017 Jan; 42(2):524-539. PubMed ID: 27550730
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
Wang XX; Xie F; Jia CC; Yan N; Zeng YL; Wu JD; Liu ZP
Eur J Med Chem; 2021 Dec; 225():113821. PubMed ID: 34517222
[TBL] [Abstract][Full Text] [Related]
11. Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Tan H; Wu W; Xu M; Pineda-Lucena A; Garcia-Osta A; Oyarzabal J
ACS Chem Neurosci; 2019 Sep; 10(9):4076-4101. PubMed ID: 31441641
[TBL] [Abstract][Full Text] [Related]
12. PTML Modeling for Alzheimer's Disease: Design and Prediction of Virtual Multi-Target Inhibitors of GSK3B, HDAC1, and HDAC6.
Kleandrova VV; Speck-Planche A
Curr Top Med Chem; 2020; 20(19):1661-1676. PubMed ID: 32515311
[TBL] [Abstract][Full Text] [Related]
13. Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.
Huang XF; Dong YH; Wang JH; Ke HM; Song GQ; Xu DF
Bioorg Med Chem Lett; 2020 May; 30(9):127097. PubMed ID: 32171616
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H
Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a fluorescent probe with HDAC6 selective inhibition.
Zhang Y; Yan J; Yao TP
Eur J Med Chem; 2017 Dec; 141():596-602. PubMed ID: 29102179
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors.
Rodrigues DA; Guerra FS; Sagrillo FS; de Sena M Pinheiro P; Alves MA; Thota S; Chaves LS; Sant'Anna CMR; Fernandes PD; Fraga CAM
ChemMedChem; 2020 Mar; 15(6):539-551. PubMed ID: 32022441
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Liang T; Xue J; Yao Z; Ye Y; Yang X; Hou X; Fang H
Eur J Med Chem; 2021 Oct; 221():113526. PubMed ID: 33992929
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of selective histone deacetylase 6 (HDAC6) inhibitors bearing benzoindazole or pyrazoloindazole scaffold as surface recognition motif.
Xu Q; Mou Y; Wang S; Gao X; Zhang Y; Wang Z; Xu X; Han Y; Jia W; Zhang M; Zhao L; Liu D
Bioorg Chem; 2021 Jun; 111():104910. PubMed ID: 33894432
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
[TBL] [Abstract][Full Text] [Related]
20. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
